SDZ.SW stock up after FY2025 biosimilars surge on SIX intraday: 1-year upside 24.30%
SDZ.SW stock is trading at CHF 65.64 on the SIX intraday session on 26 Feb 2026 after a sharp move driven by FY2025 results that highlighted strong biosimilars growth. Volume is elevated at 1,118,979.00 shares, above the 50-day average of 740,380.00, signalling heavy trader interest. We examine valuation, technicals and Meyka AI model forecasts to explain why Sandoz Group AG (SDZ.SW) is a top gainer and what to watch next.
Intraday snapshot: SDZ.SW stock performance
SDZ.SW stock opened at CHF 66.72 and is trading between a day low of CHF 64.62 and a day high of CHF 66.76 on SIX in Switzerland.
Volume today is 1,118,979.00 versus an average volume of 740,380.00, producing a relative volume of 2.75 and confirming above-normal liquidity.
What moved the price: FY2025 results and biosimilars growth
Sandoz reported FY2025 results showing a significant increase in biosimilars sales that pushed the stock higher on 25 Feb 2026.
Market reaction followed the results published in regional coverage Investing.com report which highlighted the revenue mix shift toward higher-margin biosimilars.
Valuation and financials: high P/E, solid cash flow metrics
Sandoz trades at P/E 181.05 with EPS CHF 0.40, reflecting compressed near-term earnings versus market value.
Key ratios show price-to-book 4.59 and price-to-sales 4.33, while free cash flow yield is 0.78%, underlining valuation premium versus many healthcare peers.
Balance metrics include debt-to-equity 0.65 and current ratio 1.29, indicating a manageable leverage profile but limited short-term cushion.
Technical view and trading signals for SDZ.SW stock
Momentum indicators are hot: RSI 76.61 (overbought) and MACD histogram 0.45 suggest strong upward trend but elevated short-term risk.
Price sits above the 50-day average CHF 61.04 and 200-day average CHF 51.39, confirming a bullish medium-term bias.
Meyka AI rates SDZ.SW with a score out of 100: 68.58 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus.
Meyka AI’s forecast model projects a monthly target CHF 54.91 (implied -16.35% vs CHF 65.64), a quarterly target CHF 63.47 (implied -3.31%), and a 12-month target CHF 81.59 (implied +24.30%). Forecasts are model-based projections and not guarantees.
Risks and opportunities for investors
Opportunity: faster biosimilars adoption and higher-margin portfolio mix could sustain revenue growth and lift margins.
Risk: valuation is rich with P/E 181.05, net debt-to-EBITDA near 5.91, and long inventory cycles (days of inventory on hand 225.58), which could amplify downside if growth slows.
Sector context: Healthcare peers trade at average P/E 35.67 in the sector snapshot, underscoring Sandoz’s premium.
Analyst signals, upcoming catalysts and trading plan
Market-grade data shows a company rating of B- dated 24 Feb 2026 with a neutral recommendation and mixed metric scores, including a strong sell signal on PE metrics.
Key upcoming date: earnings announcement scheduled for 2026-08-05, which could reprice expectations if guidance changes.
Traders should watch support near CHF 64.62 and resistance near the year high CHF 72.70 for intraday and swing decisions.
Final Thoughts
SDZ.SW stock is an intraday leader on SIX following FY2025 results that highlighted biosimilars growth and pushed active volumes to 1,118,979.00 shares. Valuation is the central tension: Sandoz trades at P/E 181.05 and price-to-book 4.59, signalling a premium that requires continued execution. Meyka AI’s model projects a 12-month level of CHF 81.59, implying a 24.30% upside from the current CHF 65.64, while shorter-term targets show potential pullbacks to CHF 63.47 or CHF 54.91. Investors should weigh the upside in biosimilars and improving cash flow against stretched multiples, inventory length and net-debt leverage. Use disciplined position sizing and watch the next earnings date on 2026-08-05 for updated guidance; Meyka AI provides this analysis as an AI-powered market analysis platform and not financial advice.
FAQs
What is the current price and volume for SDZ.SW stock?
SDZ.SW stock is trading at CHF 65.64 on SIX with volume 1,118,979.00 shares today, above the average volume of 740,380.00 indicating strong intraday interest.
What valuation metrics should I watch for SDZ.SW stock?
Key metrics include P/E 181.05, EPS CHF 0.40, price-to-book 4.59, and free cash flow yield 0.78%; the high P/E reflects market expectations and increases sensitivity to earnings misses.
What does Meyka AI forecast for SDZ.SW stock?
Meyka AI’s forecast model projects a 12-month target of CHF 81.59 (approx. +24.30%), with a quarterly target CHF 63.47 and monthly CHF 54.91; forecasts are model projections and not guarantees.
What are the main risks for SDZ.SW stock investors?
Major risks include stretched valuation, net-debt to EBITDA near 5.91, long inventory days (225.58), and potential margin pressure if biosimilars growth slows or pricing weakens.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.